Rationale for Long-acting Growth Hormone Therapy and Future Aspects
PDF

Review

Rationale for Long-acting Growth Hormone Therapy and Future Aspects

J Clin Res Pediatr Endocrinol 2025;17(1):1-8 DOI: 10.4274/jcrpe.galenos.2024.2023-11-8
, , ,
PDF
Permissions

Abstract

Recombinant growth hormone (GH) is administered as daily subcutaneous injections. Daily treatment can be challenging for children/adolescents, as well as for parents and/or caregivers, such as legal representatives or guardians of children in institutional care. Challenges associated with daily treatment may result in missing several doses but non-adherence with treatment leads to inadequate growth response. As an inadequate growth response does not meet criteria for continuing treatment, payers (commercial or public) may decide to end reimbursement. Novel long-acting GH (LAGH) formulations with extended half-life may be administered less frequently and aim to improve patient convenience and consequently to improve adherence and responses to treatment. LAGH formulations can restore growth velocity and body composition as effectively as daily treatment, without unexpected adverse effects, as reported in randomized clinical trials.

Keywords: Recombinant growth hormone, long-acting growth hormone, treatment adherence, review, future aspects

Read the full text

2 sections · 3 tables · PDF

Create your free account to read the full text.

  • Full text with figures and tables
  • PDF and supplementary files
  • Access on every Galenos journal
Get free access

Already have an account?

Sign in
or
Continue with Google

One Galenos account works on every Galenos journal site.

References

1

Hilczer M, Walczak M. Human growth hormone therapy - in three stages: past, present, and future. Pediatr Endocrinol Diabetes Metab. 2024;30:49-50.

2

Beck JC, McGarry EE, Dyrenfurth I, Venning EH. The metabolic effects of human and monkey growth hormone in man. Ann Intern Med. 1958;49:1090-1105.

3

Goeddel DV, Heyneker HL, Hozumi T, Arentzen R, Itakura K, Yansura DG, Ross MJ, Miozzari G, Crea R, Seeburg PH. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature. 1979;281:544-548.

4

Eslami P, Sayarifard F, Safdari R, Shahmoradi L, Karbasi Z. Global perspective on pediatric growth hormone registries: a systematic review. J Pediatr Endocrinol Metab. 2022;35:709-726.

5

Ranke MB, Dowie J. KIGS and KIMS as tools for evidence-based medicine. Horm Res. 1999;51(Suppl 1):83-86.

6

Kastrup KW, Christiansen JS, Andersen JK, Orskov H. Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children. Acta Endocrinol (Copenh). 1983;104:148-152.

7

Albertsson-Wikland K, Westphal O, Westgren U. Daily subcutaneous administration of human growth hormone in growth hormone deficient children. Acta Paediatr Scand. 1986;75:89-97.

8

Ranke MB, Wit JM. Growth hormone - past, present, and future. Nat Rev Endocrinol. 2018;14:285-300. Epub 2018 Mar 16

9

de Arriba Muñoz A, Muñiz VC, Saez JJA, Beisti A, Llovet E, Aizpún JIL. Impact of adherence on growth response during the first 2 years of growth hormone treatment. Endocrine. 2021;72:513-523. Epub 2020 Dec 7

10

Gomez R, Ahmed SF, Maghnie M, Li D, Tanaka T, Miller BS. Treatment adherence to injectable treatments in pediatric growth hormone deficiency compared with injectable treatments in other chronic pediatric conditions: a systematic literature review. Front Endocrinol (Lausanne). 2022;13:795224.

11

Aycan Z, Araslı Yılmaz A, Yel S, Savaş-Erdeve Ş, Çetinkaya S. Evaluation of growth hormone results in different diagnosis and trend over 10 year of follow-up: a single center experience. J Clin Res Pediatr Endocrinol. 2021;13:332-341.

12

Aydın BK, Aycan Z, Sıklar Z, Berberoğlu M, Ocal G, Cetinkaya S, Baş VN, Kendirci HN, Cetinkaya E, Darcan S, Gökşen D, Evliyaoğlu O, Sükür M, Baş F, Darendeliler F. Adherence to growth hormone therapy: results of a multicenter study. Endocr Pract. 2014;20:46-51.

13

Ben-Ari T, Chodick G, Shalev V, Goldstein D, Gomez R, Landau Z. Real-world treatment patterns and outcomes of growth hormone treatment among children in Israel over the past decade (2004-2015). Front Pediatr. 2021;9:711979.

14

Cutfield WS, Derraik JG, Gunn AJ, Reid K, Delany T, Robinson E, Hofman PL. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One. 2011;6:e16223.

15

Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr. 2013;79:189-196.

16

Wit JM, Deeb A, Bin-Abbas B, Al Mutair A, Koledova E, Savage MO. Achieving optimal short- and long-term responses to paediatric growth hormone therapy. J Clin Res Pediatr Endocrinol. 2019;11:329-340. Epub 2019 Jul 9

17

Rosenfeld RG, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract. 2008;14:143-154.

18

Mohseni S, Heydari Z, Qorbani M, Radfar M. Adherence to growth hormone therapy in children and its potential barriers. J Pediatr Endocrinol Metab. 2018;31:13-20.

19

Yuen KCJ, Miller BS, Boguszewski CL, Hoffman AR. Usefulness and potential pitfalls of long-acting growth hormone analogs. Front Endocrinol (Lausanne). 2021;12:637209.

20

Baltaci AK, Mogulkoc R, Baltaci SB. Review: the role of zinc in the endocrine system. Pak J Pharm Sci. 2019;32:231-239.

21

Vanderkuur JA, Butch ER, Waters SB, Pessin JE, Guan KL, Carter-Su C. Signaling molecules involved in coupling growth hormone receptor to mitogen-activated protein kinase activation. Endocrinology. 1997;138:4301-4307.

22

Jose B, Tahrani AA, Piya MK, Barnett AH. Exenatide once weekly: clinical outcomes and patient satisfaction. Patient Prefer Adherence. 2010;4:313-324.

23

Johnston K, Stoffman JM, Mickle AT, Klaassen RJ, Diles D, Olatunde S, Eliasson L, Bahar R. Preferences and health-related quality-of-life related to disease and treatment features for patients with hemophilia a in a Canadian general population sample. Patient Prefer Adherence. 2021;15:1407-1417.

24

Chatelain P, Malievskiy O, Radziuk K, Senatorova G, Abdou MO, Vlachopapadopoulou E, Skorodok Y, Peterkova V, Leff JA, Beckert M; TransCon GH Working Group. A randomized phase 2 study of long-acting transcon GH vs daily GH in childhood GH deficiency. J Clin Endocrinol Metab. 2017;102:1673-1682.

25

Thygesen P, Andersen HS, Behrens C, Fels JJ, Nørskov-Lauritsen L, Rischel C, Johansen NL. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: a reversible non-covalent albumin-binding growth hormone. Growth Horm IGF Res. 2017;35:8-16. Epub 2017 May 24

26

Miller BS, Blair JC, Rasmussen MH, Maniatis A, Kildemoes RJ, Mori J, Polak M, Bang RB, Böttcher V, Stagi S, Horikawa R. Weekly somapacitan is effective and well tolerated in children with gh deficiency: the randomized phase 3 REAL4 trial. J Clin Endocrinol Metab. 2022;107:3378-3388.

27

Rivolo S, Loftus J, Peter B, Fahey M, Kongnakorn T. Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland. J Med Econ. 2023;26:963-972.

28

Johannsson G. Long-acting growth hormone for replacement therapy. J Clin Endocrinol Metab. 2011;96:1668-1670.

29

Miller BS. What do we do now that the long-acting growth hormone is here? Front Endocrinol (Lausanne). 2022;13:980979.

30

Lamb YN. Somatrogon: First Approval. Drugs. 2022;82:227-234.

31

Steiner M, Frank J, Saenger P. Long-acting growth hormone in 2022. Pediatr Investig. 2023;7:36-42.

32

Zadik Z, Zelinska N, Iotova V, Skorodok Y, Malievsky O, Mauras N, Valluri SR, Pastrak A, Rosenfeld R. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment. J Pediatr Endocrinol Metab. 2023;36:261-269.

33

Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, Kim HS, Ko C, Malievskiy O, Cara JF, Roland CL, Taylor CT, Valluri SR, Wajnrajch MP, Pastrak A, Miller BS. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab. 2022;107:2717-2728.

34

Gomez R, Lamoureux R, Turner-Bowker DM, Loftus J, Maghnie M, Miller BS, Polak M, Yaworsky A. Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study. Front Endocrinol (Lausanne). 2023;14:1254424.

35

Maniatis AK, Carakushansky M, Galcheva S, Prakasam G, Fox LA, Dankovcikova A, Loftus J, Palladino AA, de Los Angeles Resa M, Turich Taylor C, Dattani MT, Lebl J. Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study. J Endocr Soc. 2022;6:bvac117.

36

Rivolo S, Loftus J, Peter B, Fahey M, Kongnakorn T. Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland. J Med Econ. 2023;26:963-972.

37

Zelinska N, Iotova V, Skorodok J, Malievsky O, Peterkova V, Samsonova L, Rosenfeld RG, Zadik Z, Jaron-Mendelson M, Koren R, Amitzi L, Raduk D, Hershkovitz O, Hart G. Long-acting C-terminal peptide-modified hGH (MOD-4023): results of a safety and dose-finding study in GHD children. J Clin Endocrinol Metab. 2017;102:1578-1587.

38

Mameli C, Orso M, Calcaterra V, Wasniewska MG, Aversa T, Granato S, Bruschini P, Guadagni L, d’Angela D, Spandonaro F, Polistena B, Zuccotti G. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: a systematic review and meta-analysis. Pharmacol Res. 2023;193:106805. Epub 2023 May 24

39

Sävendahl L, Battelino T, Højby Rasmussen M, Brod M, Saenger P, Horikawa R. Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3. J Clin Endocrinol Metab. 2022;107:1357-1367.

40

Kildemoes RJ, Backeljauw PF, Højby M, Blair JC, Miller BS, Mori J, Lyauk YK. Model-based analysis of IGF-I response, dosing, and monitoring for once-weekly somapacitan in children with GH deficiency. J Endocr Soc. 2023;7:bvad115.

41

Brod M, Lee KW, Rasmussen MH. First report of disease-specific patient-reported outcomes from a randomized phase 2 trial of once-weekly somapacitan versus daily GH in children with GHD. Horm Res Paediatr. 2020;93:71-72.

42

Dos Santos JBR, Da Silva MRR. TransCon human growth hormone for children with growth hormone deficiency: a technology evaluation. Expert Opin Drug Deliv. 2022;19:1-7. Epub 2022 Jan 24

43

Lamb YN. Lonapegsomatropin: pediatric first approval. Paediatr Drugs. 2022;24:83-90.

44

Maniatis AK, Casella SJ, Nadgir UM, Hofman PL, Saenger P, Chertock ED, Aghajanova EM, Korpal-Szczyrska M, Vlachopapadopoulou E, Malievskiy O, Chaychenko T, Cappa M, Song W, Mao M, Mygind PH, Smith AR, Chessler SD, Komirenko AS, Beckert M, Shu AD, Thornton PS. Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten trial 2-year results. J Clin Endocrinol Metab. 2022;107:2680-2689.

45

Polak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915-928.

46

Dattani M, Maghnie M, Phillip M, Dahlgren J, Horikawa R, Gomez R, Kelly SP, Wajnrajch MP. PMON336 Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): a multi-country, non-interventional, prospective, cohort study of patients receiving human growth hormone treatments under routine clinical care. J Endocr Soc. 2022;6(Suppl 1):A630.

47

Chen SC, Bryce J, Chen M, Charmandari E, Choi JH, Dou X, Gong C, Hamza R, Harvey J, Hoffman AR, Horikawa R, Johannson G, Jorge AAL, Miller BS, Roehrich S, Sävendahl L, Tseretopoulou X, Vitali D, Wajnrajch M, Ahmed SF. Development of a minimum dataset for the monitoring of recombinant human growth hormone therapy in children with growth hormone deficiency: a GloBE-Reg initiative. Horm Res Paediatr. 2024;97:365-373. Last Accessed Date: 14.02.2025. Available from: https://globe-reg.net/